Company intelligence / Profile preview

GAP Innovations

Ownership: Private
Development stage: Other

Overview

GAP Innovations is developing an advanced pre-screening data analytics program aimed at improving participant selection and reducing costs/duration in CNS clinical trials. Their Bio-Hermes initiative organizes large-scale biosample databases to optimize blood-based and digital biomarkers using AI algorithms. The focus is on supporting future Alzheimer’s disease studies by streamlining recruitment and enhancing trial design with robust data-driven insights. No direct therapeutic results are reported; their impact is measured by improved efficiency in partner/future studies rather than drug efficacy outcomes at this time.

Therapeutic areas: Neurology
Modalities: Digital biomarker analyticsBlood-based biomarker analysis
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Alzheimer’s Drug Discovery Foundation

Beyond the preview

Go deeper on GAP Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAP Innovations.

Explore the full profile